Sanofi avoids EU fine over rival flu vaccine marketing case

Traders Union
All News
Financial News
Sanofi avoids EU flu vaccine fine

Highlights

Sanofi avoids a potential EU fine equalling up to 10% of global annual turnover by agreeing to marketing commitments until 2030.
Sanofi will refrain from negative promotion of CSL Seqirus' Fluad or suggesting Efluelda is safer in materials targeting healthcare professionals in France and Germany.
Sanofi must publish statements on its French and German websites clarifying both vaccines offer equivalent protection for the elderly, strengthening regulatory scrutiny in the sector.

Commitments on vaccine marketing until 2030

As reported by Reuters, the European Commission accepts Sanofi's offer to stop using promotional materials aimed at healthcare professionals in Germany and France to criticise national vaccination recommendations or to portray a competing vaccine negatively. The case centres on whether Sanofi disparages CSL Seqirus' Fluad vaccine, which competes with Sanofi's Efluelda shot, in those two markets.

The Commission says Sanofi also commits not to suggest that its own product is safer than the rival vaccine in those materials. These pledges remain in force until 2030, ending an investigation that the EU opened earlier this year.

EU antitrust chief Teresa Ribera says there should be no room for misleading information or for companies to distort public health recommendations to promote their own products. Without the commitments, the company had faced the risk of charges and a fine of as much as 10% of global annual turnover.

Implications for France and Germany vaccine competition

Sanofi is also required to publish a statement on its German and French websites within the next two years acknowledging and clarifying that the applicable national vaccination recommendations treat Fluad and Efluelda as equivalent in protecting elderly people against flu.

The decision highlights closer regulatory scrutiny of competition practices in the pharmaceutical sector, particularly where product promotion intersects with public health guidance. For the flu vaccine market in France and Germany, the outcome reinforces that commercial messaging to healthcare professionals must not conflict with official vaccination recommendations.

Our earlier article on Illumina’s new short-term credit ratings explained that the company received an 'F2' Short-Term Issuer Default Rating and an 'F2' Commercial Paper rating, reflecting strong credit quality backed by its leading position in genomic sequencing. We also noted that continued investment in innovation is expected to support medium-term revenue growth and profitability, while the ratings underscore Illumina’s ability to meet near-term obligations amid intensifying biotech competition.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.